# Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

> **NCT07084259** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Hanyang University Seoul Hospital** · enrollment: 352 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** PCSK9 inhibitor
- **DRUG:** Standard Lipid-Lowering Therapy

## Key facts

- **NCT ID:** NCT07084259
- **Lead sponsor:** Hanyang University Seoul Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2030-06
- **Final completion:** 2030-07
- **Target enrollment:** 352 (ESTIMATED)
- **Last updated:** 2025-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07084259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07084259, "Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07084259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*